MonoFIX-VF, a new mono-component factor IX concentrate: a single-centre continuous-infusion study.
MonoFIX-VF, a monocomponent factor IX concentrate, has replaced the use of Prothrombinex-HT as the treatment of choice for patients with factor IX deficiency in Australia. The haemostatic effect of MonoFIX-VF, administered by continuous infusion, was assessed in four subjects being treated for 10 bleeding episodes including five surgical procedures. MonoFIX-VF was found to be a safe and effective treatment for patients with haemophilia B.
Haemophilia Centre, Kent and Canterbury Hospital, Canterbury, Kent, UK. gillian.evans@ernt.nhs.uk
G
G
Evans
M
M
Collett
N
N
Came
J
J
Lloyd
L
L
Powell
A
A
Street
D004341:Drug Evaluation / Q000379:methods*; D005164:Factor IX / Q000008:administration & dosage* / Q000493:pharmacokinetics; D006679:HIV Seropositivity / Q000150:complications; D006207:Half-Life; D002836:Hemophilia B / Q000628:therapy* / Q000821:virology; D006488:Hemostasis, Surgical / Q000379:methods; D006489:Hemostatic Techniques; D006801:Humans; D007262:Infusions, Intravenous; D008297:Male
D005164:Factor IX